ReviewBritish journal of pharmacology2009
Emerging pharmacology and physiology of neuromedin U and the structurally related peptide neuromedin S.
Review in British journal of pharmacology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed.
- The Concise Guide to PHARMACOLOGY 2025/26: G protein-coupled receptors.British journal of pharmacology · 2025Review
- The peptide neuromedin U (NMU) is elevated in NYHA II and III heart failure.ESC heart failure · 2024Article
- The Concise Guide to PHARMACOLOGY 2023/24: G protein-coupled receptors.British journal of pharmacology · 2023Article
- Neuroanatomical characterization of the Nmu-Cre knock-in mice reveals an interconnected network of unique neuropeptidergic cells.Open biology · 2023Article
- Tritium Labeling of Neuromedin S by Conjugation with [ACS omega · 2023Article
- Neuromedin U secreted by colorectal cancer cells promotes a tumour-supporting microenvironment.Cell communication and signaling : CCS · 2022Article
- Neuromedin U-deficient rats do not lose body weight or food intake.Scientific reports · 2022Article
- Neuromedin U induces an invasive phenotype in CRC cells expressing the NMUR2 receptor.Journal of experimental & clinical cancer research : CR · 2021Article
- Neuromedin U uses Gαi2 and Gαo to suppress glucose-stimulated Ca2+ signaling and insulin secretion in pancreatic β cells.PloS one · 2021Article
- Neuromedins NMU and NMS: An Updated Overview of Their Functions.Frontiers in endocrinology · 2021Review
- Neuromedin U: potential roles in immunity and inflammation.Immunology · 2021Review
- Effects of fast-track anesthesia on miR-1 and neuropeptides in serum of patients undergoing cardiac surgery.Experimental and therapeutic medicine · 2020Article
- Article
- Effect of neuromedin U on allergic airway inflammation in an asthma model.Experimental and therapeutic medicine · 2020Review
- Pharmacological Manipulation of the Circadian Clock: A Possible Approach to the Management of Bipolar Disorder.CNS drugs · 2019Review
- Comparison of glucose tolerance between wild-type mice and mice with double knockout of neuromedin U and neuromedin S.The Journal of veterinary medical science · 2019Article
- Review
- Synthesis andACS medicinal chemistry letters · 2018Article
- Differential effects of selective agonists of neuromedin U1 and U2 receptors in obese and diabetic mice.British journal of pharmacology · 2018Article
- Effects of peripheral administration of a Neuromedin U receptor 2-selective agonist on food intake and body weight in obese mice.International journal of obesity (2005) · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Neuromedin U (NMU) has been paired with the G-protein-coupled receptors (GPRs) NMU(1) (formerly designated as the orphan GPR66 or FM-3) and NMU(2) (FM-4 or hTGR-1). Recently, a structurally related peptide, neuromedin S (NMS), which shares an amidated C-terminal heptapeptide motif, has been identified in both rat and human, and has been proposed as a second ligand for these receptors. Messenger RNA encoding NMU receptor subtypes shows differential expression: NMU(1) is predominantly expressed in peripheral tissues, particularly the gastrointestinal tract, whereas NMU(2) is abundant within the brain and spinal cord. NMU peptide parallels receptor distribution with highest expression in the gastrointestinal tract and specific structures within the brain, reflecting its major role in the regulation of energy balance. The NMU knockout mouse has an obese phenotype and, in agreement, the Arg165Trp amino acid variant of NMU-25 in humans, which is functionally inactive, co-segregated with childhood-onset obesity. Emerging physiological roles for NMU include vasoconstriction mediated predominantly via NMU(1) with nociception and bone remodelling via NMU(2). The NMU system has also been implicated in the pathogenesis of septic shock and cancers including bladder carcinoma and acute myeloid leukaemia. Intriguingly, NMS is more potent at NMU(2) receptors in vivo where it has similar central actions in suppression of feeding and regulation of circadian rhythms to NMU. Taken together with its vascular actions, NMU may be a functional link between energy balance and the cardiovascular system and may provide a future target for therapies directed against the disorders that comprise metabolic syndrome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.